GLP-1s and Fatty Liver Disease (MASLD/MASH): The Evidence

Fatty liver disease has a new name. What used to be called NAFLD is now MASLD (metabolic dysfunction-associated steatotic liver disease), and its inflammatory, scarring form — once NASH — is now MASH. As of August 2025, one GLP-1 medicine is FDA-approved for the liver: semaglutide at the Wegovy 2.4 mg dose, cleared for noncirrhotic MASH with moderate-to-advanced fibrosis. That makes it the first GLP-1 — and the second drug of any kind, after resmetirom (Rezdiffra) in 2024 — approved for MASH. Every other GLP-1, tirzepatide included, is used off-label or is still investigational for the liver. For a midlife woman whose fatty liver rides alongside excess weight or type 2 diabetes, a GLP-1 may help the liver mainly by treating those drivers — but diagnosis, staging and treatment are specialist-led, and weight loss, blood-sugar control and cutting alcohol remain the foundation.

What do MASLD and MASH actually mean?

In 2023, the American Association for the Study of Liver Diseases (AASLD) and other international liver societies retired the old “non-alcoholic” labels. The reasons were partly stigma and partly accuracy: the disease is defined by metabolism, not by what a person does not do. The new names describe what is actually happening.

• MASLD means there is fat in the liver and at least one cardiometabolic risk factor — excess weight or waist size, raised blood sugar or type 2 diabetes, high blood pressure, or abnormal cholesterol or triglycerides.
• MASH is the more serious end: the fatty liver has become inflamed and liver cells are being injured, which over years can lay down scar tissue (fibrosis) and, at its worst, cirrhosis.

Most people with MASLD never progress to MASH. But MASH is the form that threatens the liver, and it is the form the new drugs are tested against. The table below maps the terms and where GLP-1 medicines currently sit.

Why does fatty liver rise in midlife women?

Before menopause, women get some liver protection from estrogen, which helps regulate how the body handles fat and insulin. As estrogen falls in perimenopause and after, that protection fades: visceral fat around the middle rises, insulin resistance increases, and fat is more likely to accumulate in the liver. Studies find postmenopausal women have roughly 1.5-to-2 times the rate of fatty liver of premenopausal women, even after accounting for age and body weight. Conditions that cluster in women — insulin resistance, type 2 diabetes and PCOS — push the risk higher still. This is the same metabolic shift behind stubborn midlife weight gain, which is exactly why a medicine that improves metabolism has drawn interest for the liver.

Which drugs are actually approved for MASH?

Two — and it is worth being precise about which is which:

• Resmetirom (Rezdiffra) — approved by the FDA in March 2024 as the first medicine ever for MASH. It is not a GLP-1; it is a thyroid hormone receptor-beta agonist that acts directly in the liver to cut fat and inflammation. It is approved for noncirrhotic MASH with moderate-to-advanced fibrosis, alongside diet and exercise.
• Semaglutide 2.4 mg (Wegovy) — granted FDA accelerated approval in August 2025 for the same population: adults with noncirrhotic MASH and moderate-to-advanced fibrosis (roughly stages F2–F3), not cirrhosis. This is the first GLP-1 approved for the liver.

“Accelerated approval” is worth understanding. It means the FDA cleared the drug on a likely-to-benefit surrogate — liver histology — while the full outcome trial continues. It is a genuine approval, not a guess, but the long-term liver-outcome data are still being gathered. The dose and brand also matter: the MASH approval is for the 2.4 mg Wegovy dose, not the lower semaglutide doses sold for diabetes as Ozempic. We do not name starting doses here; that is your prescriber's call.

How strong is the GLP-1 evidence?

Genuinely promising — and, for semaglutide, now trial-grade. In the phase 3 ESSENCE trial, published in the New England Journal of Medicine in 2025, adults with MASH and fibrosis took weekly semaglutide 2.4 mg or placebo for 72 weeks. About 63% on semaglutide had resolution of steatohepatitis without their fibrosis worsening, versus 34% on placebo; and 37% had their fibrosis improve without MASH worsening, versus 22% on placebo. Those are meaningful differences measured on liver biopsy, not just on a scan.

Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 medicine, was tested in the phase 2 SYNERGY-NASH trial (NEJM, 2024): at 52 weeks, MASH resolved in roughly 52–73% of participants across doses versus 13% on placebo, with fibrosis improving in more than half. Encouraging — but phase 2, and tirzepatide is not FDA-approved for the liver, so any liver use is off-label. Other agents, such as the glucagon/GLP-1 drug survodutide, are earlier still and remain investigational. In November 2025 the AASLD updated its practice guidance to add semaglutide as an option for MASH — after lifestyle, and alongside resmetirom — which is the honest place the evidence sits today.

Across all of them, the leading explanation for the liver benefit is not a mysterious liver effect. It is what GLP-1s do — substantial weight loss and better blood-sugar control — feeding back to a fatty, inflamed liver.

Where GLP-1s fit if you have fatty liver in midlife

For most midlife women, fatty liver travels with the metabolic package: extra weight, rising blood sugar, an unfriendly lipid panel. Treat that package and the liver usually improves. That is why the levers with the most evidence are still behavioural. AASLD guidance points to weight loss as the cornerstone: losing about 3–5% of body weight tends to reduce liver fat, 7–10% is where inflammation and scarring start to improve, and losses above 10% can resolve MASH in a large share of people. Mediterranean-style eating plus a mix of aerobic and resistance exercise are the best-studied ways to get there.

A GLP-1 enters the picture when those drivers are hard to shift on their own — particularly for a woman who also has obesity or type 2 diabetes, where a GLP-1 is already an appropriate treatment in its own right and the liver benefit is a bonus. Deciding whether your liver disease has reached the stage that warrants drug treatment is not a self-diagnosis. Fibrosis staging — through blood-based scores, elastography (a “FibroScan”), or occasionally biopsy — is done by a clinician, usually a hepatologist or gastroenterologist, and it determines everything that follows. MASH is a chronic, clinician-managed condition, not something a medication cures on its own.

One more foundation: alcohol. Even moderate drinking adds fat and injury to a liver that is already struggling, and the new nomenclature carves out MetALD precisely for people whose fat is driven by both metabolism and alcohol. No GLP-1 offsets ongoing drinking — cutting back is one of the highest-yield things you can do. See alcohol and menopause.

Safety questions women ask

Birth control. Here the two lead drugs differ, and it matters. Tirzepatide's label warns that it can make oral hormonal contraceptives less reliable — because it slows stomach emptying — and advises using a non-oral method or adding a barrier method for four weeks after starting and after each dose increase. Semaglutide's label carries no such warning. Which contraceptive to use, and any switch, is a decision for you and your prescriber, not something to change on your own.

Pregnancy. GLP-1s are not considered safe in pregnancy. The labels advise stopping the medicine before a planned pregnancy, and because these drugs linger in the body, that timing is deliberately built in — follow your clinician's guidance, not a rule of thumb.

Compounded and grey-market versions. Cost drives many people toward compounded “semaglutide” or “tirzepatide” sold online. These are not FDA-approved products, dosing errors with them have caused real harm, and nothing about a compounded vial has been tested for the liver. If cost is the barrier, price the approved options first with our cost & coverage estimator, and read how to get a GLP-1 online safely before buying anything.

“Microdosing” and longevity claims. Marketing that pitches tiny GLP-1 doses for “liver detox,” anti-ageing or general wellness is running well ahead of the evidence. The liver benefit in trials came from full, studied doses producing real weight loss — not from sub-therapeutic microdoses. Treat those claims as marketing, and take liver concerns to a clinician.

When to see a doctor

Fatty liver is usually silent, which is exactly why it gets missed. Talk to a clinician about screening and staging if you:

• Have obesity, type 2 diabetes, prediabetes, PCOS, or a raised waist measurement — especially around and after menopause;
• Have had abnormal liver enzymes on a blood test, or fatty liver mentioned on an ultrasound or scan;
• Are considering — or already taking — a GLP-1 and want to know whether your liver needs its own assessment.

Seek care promptly, without waiting for a routine appointment, if you develop severe or persistent abdominal pain (especially pain that bores through to your back, which can signal pancreatitis — a known GLP-1 risk), yellowing of the skin or eyes, swelling of the abdomen, confusion, or vomiting that stops you keeping fluids down. And if you are taking a GLP-1 and think you might be pregnant, contact your clinician right away. None of the decisions here — starting, stopping, switching or dosing any medication — should be made alone; every one is your prescriber's to make with you.

The bottom line: the evidence that GLP-1s help the metabolic liver is real and, for semaglutide, now strong enough for an FDA MASH approval. But it works by fixing the drivers — weight, blood sugar, and the metabolic shift of midlife — which means the medicine is one tool inside a plan led by your clinician and built on weight loss, movement and less alcohol.